Literature DB >> 32234404

Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Melody P Chung1, Carrie Richardson2, David Kirakossian3, Amir B Orandi4, Lesley A Saketkoo5, Lisa G Rider6, Adam Schiffenbauer6, Carlos A von Mühlen7, Lorinda Chung8.   

Abstract

Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy characterized by muscle weakness and cutaneous manifestations in adults and children. Calcinosis, a complication of DM, is the abnormal deposition of insoluble calcium salts in tissues, including skin, subcutaneous tissue, tendons, fascia, and muscle. Calcinosis is more commonly seen in juvenile DM (JDM), but also develops in adult DM. Although the mechanism of calcinosis remains unclear, several pathogenic hypotheses have been proposed, including intracellular accumulation of calcium secondary to an alteration of the cellular membrane by trauma and inflammation, local vascular ischemia, dysregulation of mechanisms controlling the deposition and solubility of calcium and phosphate, and mitochondrial damage of muscle cells. Identifying calcinosis biomarkers is important for early disease detection and risk assessment, and may lead to novel therapeutic targets for the prevention and treatment of DM-associated calcinosis. In this review, we summarize myositis autoantibodies associated with calcinosis in DM, histopathology and chemical composition of calcinosis, genetic and inflammatory markers that have been studied in adult DM and JDM-associated calcinosis, as well as potential novel biomarkers. Published by Elsevier B.V.

Entities:  

Keywords:  Autoantibodies; Calcinosis; Dermatoyositis

Mesh:

Substances:

Year:  2020        PMID: 32234404      PMCID: PMC7225028          DOI: 10.1016/j.autrev.2020.102533

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  111 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

2.  Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Authors:  Jemima Albayda; Iago Pinal-Fernandez; Wilson Huang; Cassie Parks; Julie Paik; Livia Casciola-Rosen; Sonye K Danoff; Cheilonda Johnson; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11       Impact factor: 4.794

3.  Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis.

Authors:  Kazumitsu Sugiura; Yoshinao Muro; Masashi Akiyama
Journal:  J Am Acad Dermatol       Date:  2012-10       Impact factor: 11.527

4.  Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Authors:  Antonia Valenzuela; Lorinda Chung; Livia Casciola-Rosen; David Fiorentino
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

5.  Dermatomyositis with calcinosis cutis. Case report 317.

Authors:  D Magid; E K Fishman; S S Siegelman
Journal:  Skeletal Radiol       Date:  1985       Impact factor: 2.199

6.  Differential Clinical Associations of Anti-Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies.

Authors:  Hanbo Yang; Xin Lu; Qinglin Peng; Wei Jiang; Jingli Shi; Yamei Zhang; He Chen; Guochun Wang
Journal:  Arthritis Rheumatol       Date:  2018-06-27       Impact factor: 10.995

7.  Severe calcinosis cutis with cutaneous ulceration in juvenile dermatomyositis.

Authors:  Bijay Kumar Meher; Pravakar Mishra; Pradeep Sivaraj; Prasanta Padhan
Journal:  Indian Pediatr       Date:  2014-11       Impact factor: 1.411

8.  Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

Authors:  Gulnara Mamyrova; Terrance P O'Hanlon; Jason B Monroe; Danielle Mercatante Carrick; James D Malley; Sharon Adams; Ann M Reed; Ejaz A Shamim; Laura James-Newton; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-12

9.  Vitamin K dependent modifications of glutamic acid residues in prothrombin.

Authors:  J Stenflo; P Fernlund; W Egan; P Roepstorff
Journal:  Proc Natl Acad Sci U S A       Date:  1974-07       Impact factor: 11.205

10.  Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis.

Authors:  J P Brown; P D Delmas; L Malaval; C Edouard; M C Chapuy; P J Meunier
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

View more
  9 in total

Review 1.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592

Review 2.  [Recent research on tofacitinib in the treatment of pediatric rheumatic diseases].

Authors:  Shi-Hai Zhou; Ya-Qun Xiong; Ya Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

Review 3.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 4.  Updated Role of High-frequency Ultrasound in Assessing Dermatological Manifestations in Autoimmune Skin Diseases.

Authors:  Ke Chai; Ruixuan Zhu; Fujian Luo; Yaqian Shi; Minghui Liu; Yangfan Xiao; Rong Xiao
Journal:  Acta Derm Venereol       Date:  2022-08-24       Impact factor: 3.875

Review 5.  Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis.

Authors:  Rochelle L Castillo; Alisa N Femia
Journal:  Ann Transl Med       Date:  2021-03

6.  Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.

Authors:  Natasa Toplak; Pallavi Pimpale Chavan; Silvia Rosina; Tomas Dallos; Oz Rotem Semo; Cassyanne L Aguiar; Raju Khubchandani; Angelo Ravelli; Anjali Patwardhan
Journal:  Front Pediatr       Date:  2022-02-23       Impact factor: 3.418

7.  S1P defects cause a new entity of cataract, alopecia, oral mucosal disorder, and psoriasis-like syndrome.

Authors:  Fuying Chen; Cheng Ni; Xiaoxiao Wang; Ruhong Cheng; Chaolan Pan; Yumeng Wang; Jianying Liang; Jia Zhang; Jinke Cheng; Y Eugene Chin; Yi Zhou; Zhen Wang; Yiran Guo; She Chen; Stephanie Htun; Erin F Mathes; Alejandra G de Alba Campomanes; Anne M Slavotinek; Si Zhang; Ming Li; Zhirong Yao
Journal:  EMBO Mol Med       Date:  2022-04-01       Impact factor: 14.260

8.  Assessment of Treatment Response by Bone SPECT-CT in a Case of Dermatomyositis with Calcinosis Cutis.

Authors:  P Sai Sradha Patro; Subhabrata Patra; Rajesh Kumar; Kanhaiyalal Agrawal; Girish Kumar Parida
Journal:  Indian J Nucl Med       Date:  2022-03-25

9.  Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy.

Authors:  Lauren M Pachman; Brian E Nolan; Deidre DeRanieri; Amer M Khojah
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.